Drug Trial Radar · NCT07951762
A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
368
Planned (sponsor's estimate)
Start
Dec 30, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
SYS6043+PD-1/VEGF bispecific antibodyDrug
SYS6043: IV PD-1/VEGF bispecific antibody: IV
SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.Drug
SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV
SYS6043 monotherapyDrug
SYS6043: IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Incidences of AEsTime frame: From the signing of the informed consent form until 90 days after the last dose.
- Phase I: DLTTime frame: 21 days
- Phase I: MTD/RP2DTime frame: After phase I dose escalation stage. Approximately 4 months.
- Phase II: ORRTime frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.